| A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease (EASi-PROTKT™) |
Ongoing |
Vicadrostat (BI 690517) / Empagliflozin |
3 |
1378-0041 |
Imam Abdulrahman University Hospital (Dammam) , King Abdulaziz University Hospital (Jeddah) , King Faisal Specialist Hospital and Research Center (Riyadh) , King Saud University Medical City (Riyadh) |
| A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. |
Ongoing |
SAR445229 (Amlitelimab) |
3 |
LTS17367 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE) |
Ongoing |
Dostarlimab (GSK4057190) |
3 |
221530 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Saud University Medical City (Riyadh), King Abdullah International Medical Research Center (Riyadh) |
| A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia (EMERALD2) |
Ongoing |
Patiromer |
2 |
RLY5016-208p |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Saud University Medical City (Riyadh) |
| A Phase 2 Study for the Treatment of Anemia with Alpha (α)-Thalassemia to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) in Adults and Evaluate the Safety and Pharmacokinetics in Adolescents |
Ongoing |
Luspatercept |
2 |
CA056015 |
King Khalid University Hospital (Riyadh),National Guard Health Affairs (Alahsa) |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of Povetacicept In Adults With Immunoglobulin A Nephropathy (Rainier) |
Ongoing |
Povetacicept |
3 |
AIS-D08 |
King Saud University Medical City (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh) |
| Impact of an Oxygen-Loaded Sustained-Release Hyaluronic Acid Hydrogel on Periodontal Pocket Depth Reduction and Pain Control: A Split-Mouth Randomized Clinical Trial |
Ongoing |
Hyaluronic acid and Oxygel gel |
4 |
OHGel2025 |
Dental Hospital of King Khalid University (Abha) |
| A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis |
Ongoing |
Survodutide |
3 |
1404-0064 |
King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN) |
Ongoing |
Rapcabtagene autoleucel (YTB323) |
2 |
CYTB323J12201 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| An Open-Label, Multi-Centre, Rollover Study to Characterise Long-Term Safety and Efficacy of Etavopivat In Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia And Have Completed A Treatment Period in An Etavopivat Study |
Ongoing |
Etavopivat |
3 |
NN7535-7822 |
Prince Mohammad Bin Naser Hospital (Jazan),King Khalid University Hospital (Riyadh) |
